期刊
FEBS LETTERS
卷 588, 期 8, 页码 1349-1364出版社
WILEY
DOI: 10.1016/j.febslet.2014.02.047
关键词
Connexin43; Gap junction; ACT1 peptide; Wound healing; CNS; Cancer; Therapeutic; Purinergic
资金
- National Institutes of Health [R43 EY021965, R43 DK080567, R44 DK080567, R42 AR053798]
- National Science Foundation [IIP-121514]
Gap junctions and their connexin components are indispensable in mediating the cellular coordination required for tissue and organ homeostasis. The critical nature of their existence mandates a connection to disease while at the same time offering therapeutic potential. Therapeutic intervention may be offered through the pharmacological and molecular disruption of the pathways involved in connexin biosynthesis, gap junction assembly, stabilization, or degradation. Chemical inhibitors aimed at closing connexin channels, peptide mimetics corresponding to short connexin sequences, and gene therapy approaches have been incredibly useful molecular tools in deciphering the complexities associated with connexin biology. Recently, therapeutic potential in targeting connexins has evolved from basic research in cell-based models to clinical opportunity in the form of human trials. Clinical promise is particularly evident with regards to targeting connexin43 in the context of wound healing. The following review is aimed at highlighting novel advances where the pharmacological manipulation of connexin biology has proven beneficial in animals or humans. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据